TY - JOUR

T1 - COVID-19 in adult acute myeloid leukemia patients

T2 - a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)

AU - Marchesi, Francesco

AU - Salmanton-García, Jon

AU - Emarah, Ziad

AU - Piukovics, Klára

AU - Nucci, Marcio

AU - López-García, Alberto

AU - Ráčil, Zdeněk

AU - Farina, Francesca

AU - Popova, Marina

AU - Zompi, Sofia

AU - Audisio, Ernesta

AU - Ledoux, Marie Pierre

AU - Verga, Luisa

AU - Weinbergerová, Barbora

AU - Szotkovski, Tomas

AU - Da Silva, Maria Gomes

AU - Fracchiolla, Nicola

AU - De Jonge, Nick

AU - Collins, Graham

AU - Marchetti, Monia

AU - Magliano, Gabriele

AU - García-Vidal, Carolina

AU - Biernat, Monika M.

AU - Van Doesum, Jaap

AU - Machado, Marina

AU - Demirkan, Fatih

AU - Al-Khabori, Murtadha

AU - Žák, Pavel

AU - Víšek, Benjamín

AU - Stoma, Igor

AU - Méndez, Gustavo Adolfo

AU - Maertens, Johan

AU - Khanna, Nina

AU - Espigado, Ildefonso

AU - Dragonetti, Giulia

AU - Fianchi, Luana

AU - Del Principe, Maria Ilaria

AU - Cabirta, Alba

AU - Ormazabal-Vélez, Irati

AU - Jaksic, Ozren

AU - Buquicchio, Caterina

AU - Bonuomo, Valentina

AU - Batinić, Josip

AU - Omrani, Ali S.

AU - Lamure, Sylvain

AU - Finizio, Olimpia

AU - Fernández, Noemí

AU - Falces-Romero, Iker

AU - Blennow, Ola

AU - Bergantim, Rui

AU - Ali, Natasha

AU - Win, Sein

AU - Van Praet, Jens

AU - Tisi, Maria Chiara

AU - Shirinova, Ayten

AU - Schönlein, Martin

AU - Prattes, Juergen

AU - Piedimonte, Monica

AU - Petzer, Verena

AU - Navrátil, Milan

AU - Kulasekararaj, Austin

AU - Jindra, Pavel

AU - Sramek, Jiří

AU - Glenthøj, Andreas

AU - Fazzi, Rita

AU - De Ramón-Sánchez, Cristina

AU - Cattaneo, Chiara

AU - Calbacho, Maria

AU - Bahr, Nathan C.

AU - El-Ashwah, Shaimaa

AU - Cordoba, Raul

AU - Hanakova, Michaela

AU - Zambrotta, Giovanni Paolo Maria

AU - Zambrotta, Giovanni

AU - Sciumè, Mariarita

AU - Booth, Stephen

AU - Rodrigues, Raquel Nunes

AU - Sacchi, Maria Vittoria

AU - García-Poutón, Nicole

AU - Martín-González, Juan Alberto

AU - Khostelidi, Sofya

AU - Gräfe, Stefanie

AU - Rahimli, Laman

AU - Ammatuna, Emanuele

AU - Busca, Alessandro

AU - Corradini, Paolo

AU - Hoenigl, Martin

AU - Klimko, Nikolai

AU - Koehler, Philipp

AU - Pagliuca, Antonio

AU - Passamonti, Francesco

AU - Cornely, Oliver A.

AU - Pagano, Livio

N1 - Publisher Copyright: ©2023 Ferrata Storti Foundation.

PY - 2023

Y1 - 2023

N2 - Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible.

AB - Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible.

UR - http://www.scopus.com/inward/record.url?scp=85136991749&partnerID=8YFLogxK

U2 - 10.3324/haematol.2022.280847

DO - 10.3324/haematol.2022.280847

M3 - Journal article

C2 - 35545919

AN - SCOPUS:85136991749

VL - 108

SP - 22

EP - 33

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 1

ER -